Discover atopic comorbidities associated with pediatric AD
Day One Biopharmaceuticals, Inc , announced that the FDA has approved Ojemda (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory BRAF-altered pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation
Novartis announced that the FDA approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastro-enteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs
A trial to determine the efficacy and safety of Lipitor (atorvastatin), from Pfizer, in preventing subclinical Atherosclerosis progression in pediatric-onset...
Bracco Diagnostics announced that the labeling of its contrast agent MultiHance (gadobenate dimeglumine) imaging contrast agent has obtained FDA approval.
The FDA has approved Dotarem (gadoterate meglumine), from Guerbet, for intravenous use with magnetic resonance imaging (MRI) in pediatric patients...
Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted...
23rd European Society for Pediatric Dermatology (ESPD) Congress from 2nd - 4th of May 2024 in Košice, Slovakia
After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches.
Background: Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children than adults. Various treatment modalities exist; however, their evidence in pediatric AA patients is lacking.